Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Mimedx Group Inc (MDXG)

Mimedx Group Inc (MDXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 905,261
  • Shares Outstanding, K 146,958
  • Annual Sales, $ 321,480 K
  • Annual Income, $ 58,230 K
  • 60-Month Beta 1.32
  • Price/Sales 2.89
  • Price/Cash Flow 33.13
  • Price/Book 6.38
Trade MDXG with:

Options Overview Details

View History
  • Implied Volatility 109.05% ( +35.29%)
  • Historical Volatility 37.74%
  • IV Percentile 96%
  • IV Rank 53.52%
  • IV High 180.96% on 04/10/24
  • IV Low 26.23% on 12/20/23
  • Put/Call Vol Ratio 1.00
  • Today's Volume 10
  • Volume Avg (30-Day) 73
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 4,525
  • Open Int (30-Day) 4,009

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 0.04
  • Number of Estimates 3
  • High Estimate 0.05
  • Low Estimate 0.03
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +166.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.10 +3.11%
on 04/19/24
8.43 -25.39%
on 03/21/24
-1.76 (-21.86%)
since 03/19/24
3-Month
6.10 +3.11%
on 04/19/24
9.04 -30.42%
on 02/29/24
-1.85 (-22.73%)
since 01/19/24
52-Week
3.37 +86.92%
on 04/20/23
9.27 -32.15%
on 12/20/23
+2.88 (+84.46%)
since 04/19/23

Most Recent Stories

More News
MiMedx Group (NASDAQ: MDXG) Reports Q1 2023 Financial Results Showing 21.7% Sales Growth

MiMedx Group, Inc. (NASDAQ: MDXG) is engaged as a biotechnology company that is focused as a placental biologics developer to

MDXG : 6.29 (+2.11%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

VCEL : 43.74 (-0.27%)
OCEL : 2.7500 (unch)
BRTX : 1.3700 (-4.86%)
MDXG : 6.29 (+2.11%)
NNVC : 1.1000 (-6.38%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

/PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one...

OCEL : 2.7500 (unch)
BRTX : 1.3700 (-4.86%)
MDXG : 6.29 (+2.11%)
NNVC : 1.1000 (-6.38%)
VCEL : 43.74 (-0.27%)
MIMEDX to Present at the Canaccord Genuity 42nd Annual Growth Conference

MARIETTA, Ga., Aug. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics...

MDXG : 6.29 (+2.11%)
MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer

Proven Biotech Executive Brings Versatile Leadership Experience MARIETTA, Ga., July 18, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG)...

MDXG : 6.29 (+2.11%)
MIMEDX Engages Nordic Bioscience Clinical Development A/S to Propel Registrational Trials of Placental Biologic Injectable for Knee Osteoarthritis

Image Analysis Group to Provide Imaging Strategy and Advanced Imaging Analytics in Support of MIMEDX’s Knee Osteoarthritis Clinical Trial Program ...

MDXG : 6.29 (+2.11%)
Prescience Point Capital Management Says MiMedx Shareholders Have Spoken: Voiced Their Desire For Change

/PRNewswire/ -- Prescience Point Capital Management LLC ("Prescience Point"), a research-focused, catalyst-driven investment firm that beneficially owns...

MDXG : 6.29 (+2.11%)
MIMEDX Shareholders Vote to Approve All Proposals at the 2022 Annual Meeting

Dr. Phyllis Gardner and James L. Bierman Reelected to Board of Directors Company Also Receives Approvals for Say-on-Pay Proposal and Qualified Employee...

MDXG : 6.29 (+2.11%)
MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2022 Annual Meeting of Shareholders

Deadline to Pre-Register is 9:00 a.m. Eastern Time on June 6, 2022 Pre-Registration Required to Attend Annual Meeting Visit www.votemimedx.com for...

MDXG : 6.29 (+2.11%)
MIMEDX Addresses Presentation by Prescience Point

Company Highlights Factually Accurate Information Already Provided Urges Shareholders to Vote “FOR” MIMEDX’s Highly Qualified and Independent Directors –...

MDXG : 6.29 (+2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. `Innovations in Regenerative Biomaterials` is the framework behind their mission to give physicians products and tissues to help the...

See More

Key Turning Points

3rd Resistance Point 6.56
2nd Resistance Point 6.43
1st Resistance Point 6.36
Last Price 6.29
1st Support Level 6.16
2nd Support Level 6.03
3rd Support Level 5.96

See More

52-Week High 9.27
Fibonacci 61.8% 7.01
Fibonacci 50% 6.32
Last Price 6.29
Fibonacci 38.2% 5.62
52-Week Low 3.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar